# SPORE in Prostate Cancer

> **NIH NIH P50** · JOHNS HOPKINS UNIVERSITY · 2024 · $2,190,123

## Abstract

Overall Project Summary/Abstract
Prostate cancer has become the most frequently diagnosed cancer in men in the United States (US) and a major
cause of cancer morbidity and mortality, with 33,000 American men (~90 every day) dying annually from the
disease. Considerable progress over the last decade resulted in the approval of multiple new hormonal and
cytotoxic therapies, each producing modest improvement in survival. Yet, despite a broad palette of therapeutic
options and the emerging promise of immunotherapy, the cure of metastatic prostate cancer has remained
elusive. However, over the past two decades, dedicated prostate cancer research, accomplished by Johns
Hopkins Prostate Cancer Program investigators and other researchers, led to a remarkable accumulation of
knowledge about the molecular mechanisms by which human prostate cancers arise and progress. These
studies identified adaptive autoregulation of androgen receptor activity, mutations and alterations in DNA-repair
pathways and an immunosuppressive microenvironment as fundamental characteristics of prostate cancer
producing resistance to hormonal, DNA-targeted and immune based therapies and allowing for progression that
eventually threatens life. To make significant advancement in the treatment of prostate cancer, the goal of this
new Prostate SPORE application is to translate new insights about the role played by adaptive changes in the
hormonal axis, DNA-repair and the immune system in the pathobiology of prostate cancer into new hypotheses
tested in clinical trials. The transcendent overall objective of the Johns Hopkins Prostate Cancer SPORE is
to reduce prostate cancer mortality via the focused pursuit of translational research in prostate cancer.

## Key facts

- **NIH application ID:** 10769303
- **Project number:** 1P50CA272391-01A1
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** Samuel R Denmeade
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $2,190,123
- **Award type:** 1
- **Project period:** 2024-09-01 → 2029-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10769303

## Citation

> US National Institutes of Health, RePORTER application 10769303, SPORE in Prostate Cancer (1P50CA272391-01A1). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10769303. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*